Medivir AB (OMX: MVIR) announces that the global second quarter net
sales of Olysio (simeprevir) amounted to 831 MUSD, of which 725 MUSD
were sales in the USA. Olysio continued a very positive sales
development and gained market shares during the quarter.
Medivir's royalties based on sales for the second quarter amounted to
500,7 MSEK (54,4 MEUR).
OLYSIO® global net sales Sales in MUSD Market Q2 2014 Q1 2014 US 725 291
RoW 106 63 Total global net sales MUSD 831 354
"The second quarter's royalty from Johnson & Johnson is obviously of
high importance for our company. However, the biggest gain is that so
many patients now can access new and effective treatments for hepatitis
C, like Olysio. This really makes a difference to patients and is a
powerful motivator for all of us in Medivir", says Maris Hartmanis,
Medivir will publish its second quarter report on August 21, 2014 at
8.30 CET followed by a conference call for investors, analysts and the
media at 14.00 CET. More information about the conference call /
audiocast will be available at www.Medivir.com.
Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was submitted
for publication at 13.55 CET on 15 July 2014.
Olysio is an NS3/4A protease inhibitor jointly developed by Janssen R&D
Ireland and Medivir AB and indicated for the treatment chronic hepatitis
C infection in combination with pegylated interferon and ribavirin in
HCV genotype 1 and 4 infected patients with compensated liver disease,
Janssen is responsible for the global clinical development of Olysio and
has exclusive, worldwide marketing rights, except in the Nordic
countries. Medivir AB retains marketing rights for Olysio in these
countries under the marketing authorization held by Janssen-Cilag
International NV. Olysio was approved for the treatment of chronic
hepatitis C infection as part of an antiviral treatment regimen in
combination with pegylated interferon and ribavirin in genotype 1
infected adults with compensated liver disease, including cirrhosis in
September 2013 in Japan, in November 2013 in Canada and the U.S. and in
March 2014 in Russia. Following the EMA approval, it is anticipated that
Olysio will be available across a number of European Union countries in
conjunction with reimbursement, in the second half of 2014. Olysio
(simeprevir) is marketed under the trade name Sovriad® in Japan and
Russia, Galexos™ in Canada and Olysio® in the U.S. and European Union.
Medivir (STO:MVIR-B) is an emerging research-based pharmaceutical
company focused on infectious diseases. Medivir has world class
expertise in polymerase and protease drug targets and drug development
which has resulted in a strong infectious disease R&D portfolio. The
Company's key pipeline asset is Olysio, a novel protease inhibitor for
the treatment of hepatitis C that is being developed in collaboration
with Janssen R&D Ireland. The company is also working with research and
development in other areas, such as bone disorders and neuropathic pain.
Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.
This information was brought to you by Cision http://news.cision.com
[ Back To NFVZone's Homepage ]